Use of inhaled corticosteroids during the first trimester of pregnancy and the risk of congenital malformations among women with asthma

Blais, Lucie; Beauchesne, Marie-France; Rey, Évelyne; Malo, Jean-Luc; Forget, Amélie
April 2007
Thorax;Apr2007, Vol. 62 Issue 4, p320
Academic Journal
Aim: To investigate whether the maternal use of different doses of inhaled corticosteroids (ICSs) during the first trimester of pregnancy for the treatment of asthma increases the risk of congenital malformations in the offspring. Methods: From the linkage of three administrative Canadian databases, a cohort of 4561 pregnancies from women with asthma who delivered between 1990 and 2000 was reconstructed. A two-stage sampling cohort design was used to acquire additional data from the woman's medical chart. Cases of congenital malformation were identified from the medical services database or the hospital database. Using refill patterns of medications, the average daily dose of ICSs used during the first trimester was calculated and categorised as follows: 0, 1–500, 500–1000 and >1000 μg/day in beclomethasone-chlorofluorocarbon equivalent. A Generalized Estimation Equation model was used to estimate the adjusted odds ratio of congenital malformation as a function of ICS daily dose. All analyses were performed for all malformations and major malformations separately. Results: Within the cohort 418 babies were identified with a congenital malformation (9.2%), 278 of which had a major malformation. About 40% of women used ICSs during the first trimester, but only 5.3% of women used >500 μg/day. The adjusted odds ratio (95% CI) for all malformations associated with the use of ICSs during the first trimester was: 0.77 (0.53 to 1.13) for 1–500, 0.41 (0.19 to 0.92) for 501–1000 and 1.00 (0.42 to 2.36) for >1000 μg/day. The corresponding figures for major malformations were 0.90 (0.64 to 1.24), 0.56 (0.22 to 1.43) and 1.67 (0.56 to 5.03). Conclusion: This study adds evidence to the safety of ICSs for the treatment of asthma during pregnancy, with regard to the likelihood of congenital malformation.


Related Articles

  • EDITORS' CHOICE. Stephenson, Paul; Sheikh, Aziz // Primary Care Respiratory Journal;Mar2013, Vol. 22 Issue 1, piii 

    An introduction is presented in which the editors discuss various reports within the issue on topics including the risk and benefit of inhaled corticosteroids (ICS) in the treatment of chronic obstructive pulmonary disease (COPD) by Price and colleagues, trend in age-adjusted prevalence of...

  • Early fetal growth and risk factors for cardiovascular disease. Aiken, Catherine E. M.; Smith, Gordon C. S. // BMJ: British Medical Journal;2/15/2014, Vol. 348 Issue 7945, p7 

    The authors discuss the need for researchers to consider the early stages of pregnancy in the evaluation of cardiovascular disease risk factors. They acknowledge feedback on a study with regard to fetal growth in the first trimester of pregnancy and development of cardiovascular disease in the...

  • Asthmatics' risk of invasive pneumococcal disease is elevated. Burke, Michael G. // Contemporary Pediatrics;Jul2005, Vol. 22 Issue 7, p16 

    This article discusses research being done on the association between asthma and the risk of invasive pneumococcal disease. The article references a study by T. R. Talbot and colleagues published in a 2005 issue of "New England Journal of Medicine." Investigators examined this association in...

  • Adding Omalizumab to the Therapy of Adolescents With Persistent Uncontrolled Moderate-Severe Allergic Asthma. Massanari, M.; Milgrom, H.; Pollard, S.; Maykut, R. J.; Kianifard, Farid; Fowler-Taylor, A.; Geba, G. P.; Zeldin, R. K. // Clinical Pediatrics;Oct2009, Vol. 48 Issue 8, p859 

    Objective. This study aimed to evaluate the effectiveness of omalizumab among adolescents with moderate-severe allergic asthma inadequately controlled with inhaled corticosteroids. Patients and methods. Data from patients 12 to 17 years of age were pooled from 5 placebo-controlled registration...

  • Salmeterol was not as effective as triamcinolone for persistent asthma. Smith, Brian J. // ACP Journal Club;Jan/Feb2002, Vol. 136 Issue 1, p14 

    Presents an abstract of the study 'Long-acting β[sub2]-agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma. A Randomized Controlled Trial,' by S. C. Lazarus, H. A. Boushey, J. V. Fahy, et al., published on the May 23, 2001 issue of the...

  • Once A Day Asthma Treatment.  // Pediatrics for Parents;1999, Vol. 18 Issue 5, p7 

    Discusses the use of the corticosteroid inhaler Pulmicort in the control of mild to moderate asthma.

  • Use of Misoprostol to Treat Incomplete Abortion Should Be Limited To the First 12 Weeks of Pregnancy. Melhado, L. // International Perspectives on Sexual & Reproductive Health;Dec2014, Vol. 40 Issue 4, p215 

    The article discusses a research study on the use of misoprostol to treat incomplete abortion among women with pregnancies of 12 weeks or fewer compared with pregnancies of 15-18 weeks, conducted in Benin, West Africa. The study examined the risk of adverse effects from misoprostol during the...

  • Care of asthma patients in relation to guidelines. Broder, Michael S.; Chang, Eunice Y.; Sapra, Sandhya // Allergy & Asthma Proceedings;Nov/Dec2010, Vol. 31 Issue 6, p452 

    Clinical asthma care may have to change to be brought in line with Expert Panel Report 3 (EPR3) guidelines, which recommend increased intensity of therapy (steps) to treat uncontrolled asthma. This study determined if asthma therapy steps can be identified using claims data and if patients have...

  • Education: Journals watch.  // GP: General Practitioner;3/17/2014, p3 

    The article presents abstracts on medical topics which include the risk for atherosclerosis and cardiovascular disease (CVC) due to obstructive sleep apnoea (OSA), inhaled corticosteroids for the management of asthma, and the risk of statins for diabetes.


Read the Article


Sign out of this library

Other Topics